Apheresis blood donation: Further Reading

Note: Canadian Blood Services offers no endorsement of and assumes no liability for the currency, accuracy, or availability of any information on these sites.

  1. Bolan CD, Greer SE, Cecco SA, Oblitas JM, Rehak NN, Leitman SF. Comprehensive analysis of citrate effects during plateletpheresis in normal donors. Transfusion 2001 Sep;41(9):1165-71. [ Full text ] [ Medline ]
  2. Bonomo P, Garozzo G, Bennardello F. The selection of donors in multicomponent collection management. Transfus Apheresis Sci. 2004 Feb; 30(1): 55-9. [Medline]
  3. Cable RG, Edwards RL. The use of platelet concentrates versus plateletpheresis - the donor perspective. Transfusion 2001 Jun;41(6):727-9. (Also see Lazarus et al. below) [ Full text ] [ Medline ]
  4. Goodnough LT, Ali S, Despotis G, Dynis M, DiPersio JF. Economic impact of donor platelet count and platelet yield in apheresis products: relevance for emerging issues in platelet transfusion therapy. Vox Sang 1999;76(1):43-9. [ Medline ]
  5. Kiprov DD, Golden P, Rohe R, Smith S, Hofmann J, Hunnicutt J. Adverse reactions associated with mobile therapeutic apheresis: analysis of 17,940 procedures. J Clin Apheresis 2001;16(3):130-3. [ Medline ]
  6. Lazarus EF, Browning J, Norman J, Oblitas J, Leitman SF. Sustained decreases in platelet count associated with multiple, regular plateletpheresis donations. Transfusion 2001 Jun;41(6):756-61. [ Full text ] [ Medline ]
  7. Strauss RG. Mechanisms of adverse effects during hemapheresis. J Clin Apheresis 1996;11(3):160-4. [ Medline ]
  8. Tran-Mi B, Storch H, Seidel K, Schulzki T, Haubelt H, Anders C, Nagel D, Siegler Ke, Vogt A, Seiler D, Hellstern P. The impact of different intensities of regular donor plasmapheresis on humoral and cellular immunity, red cell and iron metabolism, and cardiovascular risk markers. Vox Sang. 2004 Apr; 86(3): 189-97. [Medline]
  9. Vrielink H, van der Meer PF. Collection of white blood cell-reduced plasma by apheresis. Transfusion. 2004 Jun; 44(6): 917-23. [Medline]